Accelerated liver fibrosis in hepatitis B virus transgenic mice: Involvement of natural killer T cells

Hepatology

Volumn 53, Issue 1, 2011, Pages 219-229

  Jin, Zixue ^a   Sun, Rui ^a   Wei, Haiming ^a   Gao, Xiang ^b   Chen, Yongyan ^a   Tian, Zhigang ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CARBON TETRACHLORIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 1; GAMMA INTERFERON; GELATINASE A; INTERLEUKIN 13; INTERLEUKIN 4; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; COLLAGEN METABOLISM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; EXPERIMENTAL STUDY; HEPATITIS B; HEPATITIS B VIRUS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER FIBROSIS; LIVER INJURY; LIVER NODULE; LYMPHOCYTE FUNCTION; MALE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; STELLATE CELL; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE;

ANIMALS; CARBON TETRACHLORIDE POISONING; COLLAGEN TYPE I; HEPATIC STELLATE CELLS; HEPATITIS B VIRUS; INTERFERON-GAMMA; INTERLEUKIN-13; INTERLEUKIN-4; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; NATURAL KILLER T-CELLS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 78751537869     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23983     Document Type: Article

References (45)

1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218.
2. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669.
3. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76-99.
4. Senoo H. Structure and function of hepatic stellate cells. Med Electron Microsc 2004; 37: 3-15.
5. Friedman SL, Rockey DC, Bissell DM. Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference. HEPATOLOGY 2007; 45: 242-249.
6. Gutierrez-Ruiz MC, Gomez-Quiroz LE. Liver fibrosis: searching for cell model answers. Liver Int 2007; 27: 434-439.
7. Friedman SL. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 2004; 1: 98-105.
8. Williams R. Global challenges in liver disease. HEPATOLOGY 2006; 44: 521-526.
9. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538.
10. Gutierrez-Reyes G, Gutierrez-Ruiz MC, Kershenobich D. Liver fibrosis and chronic viral hepatitis. Arch Med Res 2007; 38: 644-651.
11. Mohammadzadeh Ghobadloo S, Yaghmaei B, Allameh A, Hassani P, Noorinayer B, Zali MR. Polymorphisms of glutathione S-transferase M1, T1, and P1 in patients with HBV-related liver cirrhosis, chronic hepatitis, and normal carriers. Clin Biochem 2006; 39: 46-49.
12. Xiao F, Wei H, Song S, Li G, Song C. Polymorphisms in the promoter region of the angiotensinogen gene are associated with liver cirrhosis in patients with chronic hepatitis B. J Gastroenterol Hepatol 2006; 21: 1488-1491.
13. Lin CL, Liao LY, Wang CS, Chen PJ, Lai MY, Chen DS, et al. Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. Liver Int 2005; 25: 564-570.
14. Martin-Vilchez S, Sanz-Cameno P, Rodriguez-Munoz Y, Majano PL, Molina-Jimenez F, Lopez-Cabrera M, et al. The hepatitis B virus X protein induces paracrine activation of human hepatic stellate cells. HEPATOLOGY 2008; 47: 1872-1883.
15. Sugiyama M, Tanaka Y, Kurbanov F, Maruyama I, Shimada T, Takahashi S, et al. Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes. Gastroenterology 2009; 136: 652-662.e653.
16. Safadi R, Ohta M, Alvarez CE, Fiel MI, Bansal M, Mehal WZ, et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 2004; 127: 870-882.
17. Novobrantseva TI, Majeau GR, Amatucci A, Kogan S, Brenner I, Casola S, et al. Attenuated liver fibrosis in the absence of B cells. J Clin Invest 2005; 115: 3072-3082.
18. Rivera CA, Bradford BU, Hunt KJ, Adachi Y, Schrum LW, Koop DR, et al. Attenuation of CCl(4)-induced hepatic fibrosis by GdCl(3) treatment or dietary glycine. Am J Physiol Gastrointest Liver Physiol 2001; 281: G200-207.
19. Nieto N. Oxidative-stress and IL-6 mediate the fibrogenic effects of [corrected] Kupffer cells on stellate cells. HEPATOLOGY 2006; 44: 1487-1501.
20. Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006; 130: 435-452.
21. Melhem A, Muhanna N, Bishara A, Alvarez CE, Ilan Y, Bishara T, et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 2006; 45: 60-71.
22. Park O, Jeong WI, Wang L, Wang H, Lian ZX, Gershwin ME, et al. Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. HEPATOLOGY 2009; 49: 1683-1694.
23. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009; 9: 28-38.
24. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004; 4: 583-594.
25. Safadi R, Zigmond E, Pappo O, Shalev Z, Ilan Y. Amelioration of hepatic fibrosis via beta-glucosylceramide-mediated immune modulation is associated with altered CD8 and NKT lymphocyte distribution. Int Immunol 2007; 19: 1021-1029.
26. de Lalla C, Galli G, Aldrighetti L, Romeo R, Mariani M, Monno A, et al. Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol 2004; 173: 1417-1425.
27. Chisari FV, Pinkert CA, Milich DR, Filippi P, McLachlan A, Palmiter RD, et al. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 1985; 230: 1157-1160.
28. Hou X, Zhou R, Wei H, Sun R, Tian Z. NKG2D-retinoic acid early inducible-1 recognition between natural killer cells and Kupffer cells in a novel murine natural killer cell-dependent fulminant hepatitis. HEPATOLOGY 2009; 49: 940-949.
29. Winau F, Hegasy G, Weiskirchen R, Weber S, Cassan C, Sieling PA, et al. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity 2007; 26: 117-129.
30. Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, Sharma BC, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008; 134: 1376-1384.
31. Constandinou C, Henderson N, Iredale JP. Modeling liver fibrosis in rodents. Methods Mol Med 2005; 117: 237-250.
32. Tsukamoto H, Matsuoka M, French SW. Experimental models of hepatic fibrosis: a review. Semin Liver Dis 1990; 10: 56-65.
33. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007; 117: 539-548.
34. Czochra P, Klopcic B, Meyer E, Herkel J, Garcia-Lazaro JF, Thieringer F, et al. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol 2006; 45: 419-428.
35. Tsui LV, Guidotti LG, Ishikawa T, Chisari FV. Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes. Proc Natl Acad Sci U S A 1995; 92: 12398-12402.
36. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25-36.
37. Guidotti LG, Chisari FV. Cytokine-induced viral purging-role in viral pathogenesis. Curr Opin Microbiol 1999; 2: 388-391.
38. Chen Y, Wei H, Sun R, Dong Z, Zhang J, Tian Z. Increased susceptibility to liver injury in hepatitis B virus transgenic mice involves NKG2D-ligand interaction and natural killer cells. HEPATOLOGY 2007; 46: 706-715.
39. Vilarinho S, Ogasawara K, Nishimura S, Lanier LL, Baron JL. Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus. Proc Natl Acad Sci U S A 2007; 104: 18187-18192.
40. Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST, Brenner MB. Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells. Nature 1994; 372: 691-694.
41. Sieling PA, Chatterjee D, Porcelli SA, Prigozy TI, Mazzaccaro RJ, Soriano T, et al. CD1-restricted T cell recognition of microbial lipoglycan antigens. Science 1995; 269: 227-230.
42. Lanier LL. NK cell receptors. Annu Rev Immunol 1998; 16: 359-393.
43. Notas G, Kisseleva T, Brenner D. NK and NKT cells in liver injury and fibrosis. Clin Immunol 2009; 130: 16-26.
44. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004; 4: 231-237.
45. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001; 413: 531-534.